Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Unity Software Inc (U) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Unity Software Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Unity Software Inc trades at $31 (market cap $13.48B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3× Unity Software Inc's market cap, and Unity Software Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | U | |
|---|---|---|
Market Cap | $39.89B | $13.48B |
Sector | Health | Technology |
52-Week High | $491.22 | $49.47 |
52-Week Low | $278.09 | $17.13 |
Enterprise Value | $38.15B | $13.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Unity Software (U) trades at $30.89, up 0.52% today, with a bullish technical signal and strong analyst consensus. The stock shows improving revenue trends ($1.85B in 2025) and narrowing losses, though profitability remains negative. Recent news highlights momentum in AI advertising and cost restructuring, with Q2 2026 earnings expected on August 5, 2026.
Outlook: Growth potential exists through AI integration and margin expansion, but persistent net losses and high valuation multiples pose risks. Analyst price target of $36.50 suggests 18% upside, supported by bullish sentiment, yet investors must weigh execution risks against transformative opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
